# MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT07677475** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dongguan People's Hospital** · enrollment: 65 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** MRG003 (Becotatug vedotin) and Toripalimab
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07677475
- **Lead sponsor:** Dongguan People's Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2029-01-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-08-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677475, "MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07677475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*